Patents by Inventor Tailan ZHAN

Tailan ZHAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Single-domain antibodies against CD33 and constructs thereof
    Patent number: 12275788
    Abstract: The present application provides single-domain antibodies targeting CD33 and constructs thereof, including chimeric receptors, immune effector cell engagers and immunoconjugates. Further provided are engineered immune cells (such as T cells) comprising an anti-CD33 chimeric receptor and optionally a second chimeric receptor targeting a second antigen or epitope. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: April 15, 2025
    Assignee: Legend Biotech Ireland Limited
    Inventors: Yafeng Zhang, Tailan Zhan, Fei Sun, Jian Liu, Qing Zhang, Shu Wu
  • Single-domain antibodies against CLL1 and constructs thereof
    Patent number: 12097219
    Abstract: Provided are single-domain antibodies targeting CLL1 and constructs thereof, including chimeric receptors, immune effector cell engagers and immunoconjugates. Further provided are engineered immune effector cells (such as T cells) comprising an anti-CLL1 chimeric receptor and optionally a second chimeric receptor targeting a second antigen or epitope. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: September 24, 2024
    Assignee: Legend Biotech Ireland Limited
    Inventors: Wang Zhang, Yunlei Liu, Xiaojie Tu, Chenyu Shu, Tailan Zhan, Yun Zhang, An Tang, Yafeng Zhang, Shu Wu, Qing Zhang
  • SINGLE-DOMAIN ANTIBODIES AGAINST CD33 AND CONSTRUCTS THEREOF
    Publication number: 20210275590
    Abstract: The present application provides single-domain antibodies targeting CD33 and constructs thereof, including chimeric receptors, immune effector cell engagers and immunoconjugates. Further provided are engineered immune cells (such as T cells) comprising an anti-CD33 chimeric receptor and optionally a second chimeric receptor targeting a second antigen or epitope. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
    Type: Application
    Filed: September 10, 2019
    Publication date: September 9, 2021
    Inventors: Yafeng ZHANG, Tailan ZHAN, Fei SUN, Jian LIU, Qing ZHANG, Shu WU
  • SINGLE-DOMAIN ANTIBODIES AGAINST CLL1 AND CONSTRUCTS THEREOF
    Publication number: 20210277126
    Abstract: Provided are single-domain antibodies targeting CLL1 and constructs thereof, including chimeric receptors, immune effector cell engagers and immunoconjugates. Further provided are engineered immune effector cells (such as T cells) comprising an anti-CLL1 chimeric receptor and optionally a second chimeric receptor targeting a second antigen or epitope. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
    Type: Application
    Filed: September 10, 2019
    Publication date: September 9, 2021
    Inventors: Wang ZHANG, Yunlei LIU, Xiaojie TU, Chenyu SHU, Tailan ZHAN, Yun ZHANG, An TANG, Yafeng ZHANG, Shu WU, Qing ZHANG